Tirzepatide or semaglutide use

1. Tirzepatide or semaglutide use has no effect on HDL in humans.

   “No significant changes were observed in HDL levels.”

   HumansRural-dwelling adults with prediabetes and overweight or obesity3–24 monthsn = 40

   A Retrospective Chart Review of Tirzepatide and Semaglutide Use in Prediabetes Management and Cardiometabolic Outcomes in a Rural Primary Care Setting

   Journal of doctoral nursing practice·15 Oct 2026

More on HDL

1. Tirzepatide or semaglutide use is associated with LDL and triglycerides in humans.

   “Significant improvements were observed in A1c, BMI, systolic and diastolic BP, LDL, and triglycerides (p < .001).”

   HumansRural-dwelling adults with prediabetes and overweight or obesity3–24 monthsn = 40

   A Retrospective Chart Review of Tirzepatide and Semaglutide Use in Prediabetes Management and Cardiometabolic Outcomes in a Rural Primary Care Setting

   Journal of doctoral nursing practice·15 Oct 2026

More on LDL and triglycerides

1. Tirzepatide or semaglutide use is associated with systolic and diastolic blood pressure in humans.

   “Significant improvements were observed in A1c, BMI, systolic and diastolic BP, LDL, and triglycerides (p < .001).”

   HumansRural-dwelling adults with prediabetes and overweight or obesity3–24 monthsn = 40

   A Retrospective Chart Review of Tirzepatide and Semaglutide Use in Prediabetes Management and Cardiometabolic Outcomes in a Rural Primary Care Setting

   Journal of doctoral nursing practice·15 Oct 2026

More on Systolic and diastolic blood pressure

1. Tirzepatide or semaglutide use is associated with body mass index in humans.

   “Significant improvements were observed in A1c, BMI, systolic and diastolic BP, LDL, and triglycerides (p < .001).”

   HumansRural-dwelling adults with prediabetes and overweight or obesity3–24 monthsn = 40

   A Retrospective Chart Review of Tirzepatide and Semaglutide Use in Prediabetes Management and Cardiometabolic Outcomes in a Rural Primary Care Setting

   Journal of doctoral nursing practice·15 Oct 2026

More on Body mass index

1. Tirzepatide or semaglutide use is associated with hemoglobin A1c in humans.

   “Significant improvements were observed in A1c, BMI, systolic and diastolic BP, LDL, and triglycerides (p < .001).”

   HumansRural-dwelling adults with prediabetes and overweight or obesity3–24 monthsn = 40

   A Retrospective Chart Review of Tirzepatide and Semaglutide Use in Prediabetes Management and Cardiometabolic Outcomes in a Rural Primary Care Setting

   Journal of doctoral nursing practice·15 Oct 2026

More on Hemoglobin A1c